{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05911295\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"IHC 1+ and Greater","nct_id":"NCT05911295","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ihc-1-and-greater-nct05911295. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"disitamab vedotin + pembrolizumab","label":"Disitamab vedotin arm","type":"EXPERIMENTAL"},{"description":"gemcitabine + cisplatin OR carboplatin","label":"Standard of care arm","type":"ACTIVE_COMPARATOR"}],"collaborators":["RemeGen Co., Ltd.","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2029-04-30","type":"ESTIMATED"},"conditions":["Urothelial Carcinoma"],"enrollment":{"count":412,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"disitamab vedotin","otherNames":["RC48, RC48-ADC"],"type":"DRUG"},{"name":"pembrolizumab","otherNames":["KEYTRUDA®"],"type":"DRUG"},{"name":"gemcitabine","otherNames":["Gemzar"],"type":"DRUG"},{"name":"cisplatin","otherNames":[],"type":"DRUG"},{"name":"carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-01-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)","timeFrame":"Approximately 3 years"},{"measure":"Overall survival (OS)","timeFrame":"Approximately 5 years"}],"references":[],"start_date":{"date":"2023-09-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","url":"https://clinicaltrials.gov/study/NCT05911295"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ihc-1-and-greater-nct05911295"}